Circulating microRNA expressions can predict the outcome of lenalidomide plus low-dose dexamethasone treatment in patients with refractory/relapsed multiple myeloma

• Seung-Hyun Jung,
• Sung-Eun Lee,
• Minho Lee,
• So-Hee Kim,
• Seon-Hee Yim,
• Tae Woo Kim,
• Chang-Ki Min,
• Yeun-Jun Chung

Affiliations

Seung-Hyun Jung

Departments of Cancer Evolution Research Center, The Catholic University of Korea, Seoul, South Korea;Precision Medicine Research Center, The Catholic University of Korea, Seoul, South Korea

Sung-Eun Lee

Hematology, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, South Korea

Minho Lee

Precision Medicine Research Center, The Catholic University of Korea, Seoul, South Korea

So-Hee Kim

Integrated Research Center for Genome Polymorphism, The Catholic University of Korea, Seoul, South Korea

Seon-Hee Yim

Integrated Research Center for Genome Polymorphism, The Catholic University of Korea, Seoul, South Korea

Tae Woo Kim

Hematology, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, South Korea

Chang-Ki Min

Hematology, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, South Korea;Leukemia Research Institute, The Catholic University of Korea, Seoul, South Korea

Yeun-Jun Chung

Precision Medicine Research Center, The Catholic University of Korea, Seoul, South Korea;Integrated Research Center for Genome Polymorphism, The Catholic University of Korea, Seoul, South Korea;Microbiology, College of Medicine, The Catholic University of Korea, Seoul, South Korea